Page 1

only For personal use Dimerix For Immediate Release DIMERIX QUARTERLY ACTIVITIES REPORT Quarter highlights • Second international Study to include DMX - 200 in COVID - 19 patients announced • Acute Respiratory Distress Syndrome ( ' ARDS ' ) in COVID - 19 patients protocol published Positive additional data to support DMX - 200 development in kidney diseases announced • Received R & D tax incentive refund of $ 2.3m • • DMX - 700 data demonstrated effect on key Chronic Obstructive Pulmonary Disease ( COPD ) receptors Cash position of $ 4.9 million at 31 December 2020 ( $ 4.2 million at 30 September 2020 ) MELBOURNE , Australia , 22 January 2021 : Dimerix Limited ( ASX : DXB ) ( " Dimerix " or the " Company " ) , a clinical - stage biopharmaceutical company , today announced its Appendix 4C and Quarterly Activities Report for the period ended 31 December 2020. Despite the challenges of 2020 , Dimerix started the year with two Phase 2 clinical opportunities and ended the year strongly , with data supporting the commencement of Phase 3 clinical studies for DMX - 200 in three distinct indications , as well as a fourth product opportunity in Phase 2 and a fifth product opportunity in pre - clinical development . Dimerix ended the quarter with cash of $ 4.9 million ( $ 4.2 million at 30 September 2020 ) , with net operating cash inflows for the period of $ 0.7 million ( $ 2.5 million net operating cash outflow in the prior quarter ) . The increase in total cash inflow for the quarter relative to the prior period is a result of receiving the R & D Tax Incentive rebate for the 2019/2020 financial year ( $ 2.3 million ) and decreased clinical and manufacturing expenditure . Cost management remains a key priority for the business , with the cost base being carefully managed to ensure delivery of a sustainable business beyond the current milestones . In accordance with Listing Rule 4.7C , payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors ' fees , salaries and superannuation . Dimerix continues to undertake planning for the proposed Phase 3 pivotal program in FSGS , a rare kidney disorder without an approved pharmacologic treatment that often leads to end - stage kidney failure , as well as further progress the two Phase 3 studies in COVID - 19 patients and the late Phase 2 opportunity in diabetic kidney disease , and finally advance the COPD program towards the clinical stage of development . Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs Dimerix HQ 425 Smith St , Fitzroy 3065 Victoria , Australia T. 1300 813 321 E. investor@dimerix.com